RARE shares jump 13% after-hours following FDA approval
Ultragenyx Pharmaceutical’s RARE stock extended after-hours gains after U.S. regulators approved Fayuvi, the first treatment for Sanfilippo syndrome type A.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.